1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
- Contribution to journal › Article
- 2018
-
Mark
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
Matikas, Alexios ; Lövrot, John ; Ramberg, Anna ; Eriksson, Margareta ; Lindsten, Therese ; Lekberg, Tobias ; Hedenfalk, Ingrid LU
; Loman, Niklas
LU
; Bergh, Jonas
and Hatschek, Thomas
, et al.
(2018)
In OncoImmunology
7(9).
- Contribution to journal › Article
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
Kimbung, Siker LU ; Markholm, Ida ; Bjöhle, Judith ; Lekberg, Tobias ; Wachenfeldt, von Anna ; Azavedo, Edward ; Saracco, Ariel ; Hellström, Mats ; Veerla, Srinivas LU
and Paquet, Eric
, et al.
(2018)
In International Journal of Cancer
142(3).
p.618-628
- Contribution to journal › Article